| 000 | 01378 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513183856.0 | ||
| 264 | 0 | _c19990616 | |
| 008 | 199906s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(99)00084-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTcheng, J E | |
| 245 | 0 | 0 |
_aDifferences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cMay 1999 |
||
| 300 |
_a7E-11E p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCoronary Disease _xdrug therapy |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xpharmacology |
| 650 | 0 | 4 |
_aPeptides _xpharmacology |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 |
_aTyrosine _xanalogs & derivatives |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 83 _gno. 9A _gp. 7E-11E |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(99)00084-3 _zAvailable from publisher's website |
| 999 |
_c10316195 _d10316195 |
||